1Suppliers
2Customers
2Debt Items
20Related Chains

Shattuck Labs, Inc. Suppliers

TickerNameConfidenceEvidence
INAB IN8bio, Inc. 72% Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…

Shattuck Labs, Inc. Customers

TickerNameConfidenceEvidence
KAYAK-THERAPEUTICS-INC KAYAK-THERAPEUTICS-INC 85% ffects of this economic instability on our future operations. Components of our Results of Operations Related Party License Revenue Revenue recognized in 2025 was a result of an exclusive license agr…
INAB IN8bio, Inc. 72% Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…

Shattuck Labs, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
STTK-DEBT-12807 Warrants outstanding: 40511011 90% xbrl warrant detail from xbrl 2025-12-31.
STTK-DEBT Debt stack $2.4M 90% Market cache reports total debt of $2.4M.

Shattuck Labs, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Shattuck Labs, Inc..

Shattuck Labs, Inc. Ownership

HolderNameConfidenceEvidence
STTK-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME T. Rowe Price Investment Management, Inc. 90% 13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 84 tracked holders.

Shattuck Labs, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BPTH Bio-Path Holdings, Inc. 100.00 2
GILD Gilead Sciences, Inc. 100.00 2
INAB IN8bio, Inc. 100.00 1 ['customer', 'supplier']
NRIX Nurix Therapeutics, Inc. 100.00 2
VINC Vincerx Pharma, Inc. 100.00 2
RIGL Rigel Pharmaceuticals, Inc. 100.00 2
JNJ Johnson & Johnson 100.00 2
LLY Eli Lilly and Company 100.00 2
HCWB HCW Biologics Inc. 50.00 2
CGEM Cullinan Therapeutics, Inc. 50.00 2
ADAPY Adaptimmune Therapeutics PLC 50.00 2
UABRF UABRF 50.00 2
IPSC Century Therapeutics, Inc. 50.00 2
JANX Janux Therapeutics, Inc. 50.00 2
CELG-RI BRISTOL MYERS SQUIBB CO 50.00 2
EDIT Editas Medicine, Inc. 50.00 2
REGN Regeneron Pharmaceuticals, Inc. 50.00 2
ALLO Allogene Therapeutics, Inc. 50.00 2
CRIS Curis, Inc. 36.29 1 ['spend']
ROCHE ROCHE 23.09 2